Jazz Pharmaceuticals Announces U.S. FDA Approval Of Ziihera® (Zanidatamab-Hrii) For The Treatment Of Adults With ...
(MENAFN- PR Newswire) Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of …